Two complex genotypes relevant to the kynurenine pathway and melanotropin function show association with schizophrenia and bipolar disorder

Christine L. Miller, Peter Murakami, Ingo Ruczinski, Randal G. Ross, Melissa Sinkus, Bernadette Sullivan, Sherry Leonard

Research output: Contribution to journalArticle

Abstract

Prior studies of mRNA expression, protein expression, and pathway metabolite levels have implicated dysregulation of the kynurenine pathway in the etiology of schizophrenia and bipolar disorder. Here we investigate whether genes involved in kynurenine pathway regulation might interact with genes that respond to kynurenine metabolites, to enhance risk for these psychiatric phenotypes. Candidate genes were selected from prior studies of genetic association, gene expression profiling and animal models. A single nucleotide polymorphism (SNP) in each of six genes, TDO2, HM74, HM74A, MCHR1, MCHR2 and MC5R, was tested for association with phenotype (475 Caucasians, 88 African Americans with schizophrenia; 97 Caucasians, 3 African Americans with bipolar disorder; 191 Caucasian, 49 African American controls). An A allele in HM74 was significantly associated with schizophrenia and with schizophrenia plus bipolar disorder combined, odds ratios (OR) of 1.48, p = 0.011 and 1.50, p = 0.007, respectively. Augmentation of disease risk was found for the complex genotype HM74[A,any] + MCHR1[T,any] + MCHR2[C,any] which conferred an OR maximal for the combined diagnostic category of schizophrenia plus bipolar disorder (1.70, p = 0.003), carried by 30% of the cases. TDO2[CC] + MC5R[G, any] + MCHR2[GC] conferred an OR maximal for schizophrenia alone (4.84, p = 0.005), carried by 8% of schizophrenia cases. The combined risk posed by these related, complex genotypes is greater than any identified single locus and may derive from co-regulation of the kynurenine pathway by interacting genes, a lack of adequate melanotropin-controlled sequestration of the kynurenine-derived pigments, or the production of melanotropin receptor ligands through kynurenine metabolism.

Original languageEnglish (US)
Pages (from-to)259-267
Number of pages9
JournalSchizophrenia Research
Volume113
Issue number2-3
DOIs
StatePublished - Sep 2009

Fingerprint

Kynurenine
Melanocyte-Stimulating Hormones
Bipolar Disorder
Schizophrenia
Genotype
African Americans
Genes
Odds Ratio
Phenotype
Genetic Association Studies
Gene Expression Profiling
Single Nucleotide Polymorphism
Psychiatry
Animal Models
Alleles
Ligands
Messenger RNA

Keywords

  • Gene-gene interactions
  • Metabolic
  • Niacin receptor
  • Psychosis
  • Tryptophan 2,3-dioxygenase

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Two complex genotypes relevant to the kynurenine pathway and melanotropin function show association with schizophrenia and bipolar disorder. / Miller, Christine L.; Murakami, Peter; Ruczinski, Ingo; Ross, Randal G.; Sinkus, Melissa; Sullivan, Bernadette; Leonard, Sherry.

In: Schizophrenia Research, Vol. 113, No. 2-3, 09.2009, p. 259-267.

Research output: Contribution to journalArticle

Miller, Christine L. ; Murakami, Peter ; Ruczinski, Ingo ; Ross, Randal G. ; Sinkus, Melissa ; Sullivan, Bernadette ; Leonard, Sherry. / Two complex genotypes relevant to the kynurenine pathway and melanotropin function show association with schizophrenia and bipolar disorder. In: Schizophrenia Research. 2009 ; Vol. 113, No. 2-3. pp. 259-267.
@article{b624c068ca03455b89a54b1c9f8ad720,
title = "Two complex genotypes relevant to the kynurenine pathway and melanotropin function show association with schizophrenia and bipolar disorder",
abstract = "Prior studies of mRNA expression, protein expression, and pathway metabolite levels have implicated dysregulation of the kynurenine pathway in the etiology of schizophrenia and bipolar disorder. Here we investigate whether genes involved in kynurenine pathway regulation might interact with genes that respond to kynurenine metabolites, to enhance risk for these psychiatric phenotypes. Candidate genes were selected from prior studies of genetic association, gene expression profiling and animal models. A single nucleotide polymorphism (SNP) in each of six genes, TDO2, HM74, HM74A, MCHR1, MCHR2 and MC5R, was tested for association with phenotype (475 Caucasians, 88 African Americans with schizophrenia; 97 Caucasians, 3 African Americans with bipolar disorder; 191 Caucasian, 49 African American controls). An A allele in HM74 was significantly associated with schizophrenia and with schizophrenia plus bipolar disorder combined, odds ratios (OR) of 1.48, p = 0.011 and 1.50, p = 0.007, respectively. Augmentation of disease risk was found for the complex genotype HM74[A,any] + MCHR1[T,any] + MCHR2[C,any] which conferred an OR maximal for the combined diagnostic category of schizophrenia plus bipolar disorder (1.70, p = 0.003), carried by 30{\%} of the cases. TDO2[CC] + MC5R[G, any] + MCHR2[GC] conferred an OR maximal for schizophrenia alone (4.84, p = 0.005), carried by 8{\%} of schizophrenia cases. The combined risk posed by these related, complex genotypes is greater than any identified single locus and may derive from co-regulation of the kynurenine pathway by interacting genes, a lack of adequate melanotropin-controlled sequestration of the kynurenine-derived pigments, or the production of melanotropin receptor ligands through kynurenine metabolism.",
keywords = "Gene-gene interactions, Metabolic, Niacin receptor, Psychosis, Tryptophan 2,3-dioxygenase",
author = "Miller, {Christine L.} and Peter Murakami and Ingo Ruczinski and Ross, {Randal G.} and Melissa Sinkus and Bernadette Sullivan and Sherry Leonard",
year = "2009",
month = "9",
doi = "10.1016/j.schres.2009.05.014",
language = "English (US)",
volume = "113",
pages = "259--267",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier",
number = "2-3",

}

TY - JOUR

T1 - Two complex genotypes relevant to the kynurenine pathway and melanotropin function show association with schizophrenia and bipolar disorder

AU - Miller, Christine L.

AU - Murakami, Peter

AU - Ruczinski, Ingo

AU - Ross, Randal G.

AU - Sinkus, Melissa

AU - Sullivan, Bernadette

AU - Leonard, Sherry

PY - 2009/9

Y1 - 2009/9

N2 - Prior studies of mRNA expression, protein expression, and pathway metabolite levels have implicated dysregulation of the kynurenine pathway in the etiology of schizophrenia and bipolar disorder. Here we investigate whether genes involved in kynurenine pathway regulation might interact with genes that respond to kynurenine metabolites, to enhance risk for these psychiatric phenotypes. Candidate genes were selected from prior studies of genetic association, gene expression profiling and animal models. A single nucleotide polymorphism (SNP) in each of six genes, TDO2, HM74, HM74A, MCHR1, MCHR2 and MC5R, was tested for association with phenotype (475 Caucasians, 88 African Americans with schizophrenia; 97 Caucasians, 3 African Americans with bipolar disorder; 191 Caucasian, 49 African American controls). An A allele in HM74 was significantly associated with schizophrenia and with schizophrenia plus bipolar disorder combined, odds ratios (OR) of 1.48, p = 0.011 and 1.50, p = 0.007, respectively. Augmentation of disease risk was found for the complex genotype HM74[A,any] + MCHR1[T,any] + MCHR2[C,any] which conferred an OR maximal for the combined diagnostic category of schizophrenia plus bipolar disorder (1.70, p = 0.003), carried by 30% of the cases. TDO2[CC] + MC5R[G, any] + MCHR2[GC] conferred an OR maximal for schizophrenia alone (4.84, p = 0.005), carried by 8% of schizophrenia cases. The combined risk posed by these related, complex genotypes is greater than any identified single locus and may derive from co-regulation of the kynurenine pathway by interacting genes, a lack of adequate melanotropin-controlled sequestration of the kynurenine-derived pigments, or the production of melanotropin receptor ligands through kynurenine metabolism.

AB - Prior studies of mRNA expression, protein expression, and pathway metabolite levels have implicated dysregulation of the kynurenine pathway in the etiology of schizophrenia and bipolar disorder. Here we investigate whether genes involved in kynurenine pathway regulation might interact with genes that respond to kynurenine metabolites, to enhance risk for these psychiatric phenotypes. Candidate genes were selected from prior studies of genetic association, gene expression profiling and animal models. A single nucleotide polymorphism (SNP) in each of six genes, TDO2, HM74, HM74A, MCHR1, MCHR2 and MC5R, was tested for association with phenotype (475 Caucasians, 88 African Americans with schizophrenia; 97 Caucasians, 3 African Americans with bipolar disorder; 191 Caucasian, 49 African American controls). An A allele in HM74 was significantly associated with schizophrenia and with schizophrenia plus bipolar disorder combined, odds ratios (OR) of 1.48, p = 0.011 and 1.50, p = 0.007, respectively. Augmentation of disease risk was found for the complex genotype HM74[A,any] + MCHR1[T,any] + MCHR2[C,any] which conferred an OR maximal for the combined diagnostic category of schizophrenia plus bipolar disorder (1.70, p = 0.003), carried by 30% of the cases. TDO2[CC] + MC5R[G, any] + MCHR2[GC] conferred an OR maximal for schizophrenia alone (4.84, p = 0.005), carried by 8% of schizophrenia cases. The combined risk posed by these related, complex genotypes is greater than any identified single locus and may derive from co-regulation of the kynurenine pathway by interacting genes, a lack of adequate melanotropin-controlled sequestration of the kynurenine-derived pigments, or the production of melanotropin receptor ligands through kynurenine metabolism.

KW - Gene-gene interactions

KW - Metabolic

KW - Niacin receptor

KW - Psychosis

KW - Tryptophan 2,3-dioxygenase

UR - http://www.scopus.com/inward/record.url?scp=68049135725&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68049135725&partnerID=8YFLogxK

U2 - 10.1016/j.schres.2009.05.014

DO - 10.1016/j.schres.2009.05.014

M3 - Article

C2 - 19502010

AN - SCOPUS:68049135725

VL - 113

SP - 259

EP - 267

JO - Schizophrenia Research

JF - Schizophrenia Research

SN - 0920-9964

IS - 2-3

ER -